Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative

GlobeNewswireMay 3 05:00

Institutions Own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares but Private Equity Firms Control 44% of the Company

Yahoo FinanceApr 14 21:50

Tenaya Therapeutics' Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy Rating

TipRanksApr 5 18:56

Optimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical Milestones

TipRanksMar 28 19:05

20 Countries With the Highest Heart Disease Deaths Per Capita

Yahoo FinanceMar 26 19:19

Chardan Capital Reiterates Buy on Tenaya Therapeutics, Maintains $20 Price Target

Chardan Capital analyst Geulah Livshits reiterates Tenaya Therapeutics with a Buy and maintains $20 price target.

Analyst UpgradesMar 22 00:52